Cargando…

Targeted literature review of the global burden of gastric cancer

Gastric cancer (GC) and gastroesophageal junction cancers (GEJCs) are the third leading cause of cancer-related death worldwide. Although several studies have evaluated the epidemiology and management of GC and GEJC, to our knowledge, no global estimates of the economic burden of GC and GEJC have ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Casamayor, Montserrat, Morlock, Robert, Maeda, Hiroshi, Ajani, Jaffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345079/
https://www.ncbi.nlm.nih.gov/pubmed/30679950
http://dx.doi.org/10.3332/ecancer.2018.883
_version_ 1783389524403945472
author Casamayor, Montserrat
Morlock, Robert
Maeda, Hiroshi
Ajani, Jaffer
author_facet Casamayor, Montserrat
Morlock, Robert
Maeda, Hiroshi
Ajani, Jaffer
author_sort Casamayor, Montserrat
collection PubMed
description Gastric cancer (GC) and gastroesophageal junction cancers (GEJCs) are the third leading cause of cancer-related death worldwide. Although several studies have evaluated the epidemiology and management of GC and GEJC, to our knowledge, no global estimates of the economic burden of GC and GEJC have yet been reported. This targeted literature review was conducted to summarise the epidemiology and management of GC and GEJC and to estimate its global economic and humanistic burden. The incidence of GC and GEJC is highest in Eastern Asia, several South and Central American countries and Central and Eastern Europe and lowest in North America and Africa. Prognosis is generally poor; the global 5-year survival rate is 5%–10% in advanced stages. Patients with GC and GEJC have more severe symptoms compared with patients with other cancers, and health-related quality of life (HRQoL) worsens as the disease progresses. Given the rapid progression of GC and GEJC at advanced stages, chemotherapy, despite its toxicity, improves HRQoL compared with best supportive care. The costs of GC/GEJC are generally higher than for other cancers; in the US, the average annual cost per patient between 1998 and 2003 was 46,501 USD, compared with 29,609 USD and 35,672 USD for colorectal and lung cancer, respectively. Based on the 2012 incidence data and average costs per patient, estimates of the annual financial burden of GC and GEJC revealed great regional differences. Japan and Iran had the highest (8,492 million USD) and lowest (27 million USD) costs for 2017, respectively, while the estimate for the US was 3,171 million USD. The overall annual cost of GC and GEJC estimated for 2017 in a geographic area including Europe (France, Germany, Italy, Spain and the UK), Asia (Iran, Japan and China), North America (Canada and the US) and Australia was 20.6 billion USD.
format Online
Article
Text
id pubmed-6345079
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-63450792019-01-24 Targeted literature review of the global burden of gastric cancer Casamayor, Montserrat Morlock, Robert Maeda, Hiroshi Ajani, Jaffer Ecancermedicalscience Review Gastric cancer (GC) and gastroesophageal junction cancers (GEJCs) are the third leading cause of cancer-related death worldwide. Although several studies have evaluated the epidemiology and management of GC and GEJC, to our knowledge, no global estimates of the economic burden of GC and GEJC have yet been reported. This targeted literature review was conducted to summarise the epidemiology and management of GC and GEJC and to estimate its global economic and humanistic burden. The incidence of GC and GEJC is highest in Eastern Asia, several South and Central American countries and Central and Eastern Europe and lowest in North America and Africa. Prognosis is generally poor; the global 5-year survival rate is 5%–10% in advanced stages. Patients with GC and GEJC have more severe symptoms compared with patients with other cancers, and health-related quality of life (HRQoL) worsens as the disease progresses. Given the rapid progression of GC and GEJC at advanced stages, chemotherapy, despite its toxicity, improves HRQoL compared with best supportive care. The costs of GC/GEJC are generally higher than for other cancers; in the US, the average annual cost per patient between 1998 and 2003 was 46,501 USD, compared with 29,609 USD and 35,672 USD for colorectal and lung cancer, respectively. Based on the 2012 incidence data and average costs per patient, estimates of the annual financial burden of GC and GEJC revealed great regional differences. Japan and Iran had the highest (8,492 million USD) and lowest (27 million USD) costs for 2017, respectively, while the estimate for the US was 3,171 million USD. The overall annual cost of GC and GEJC estimated for 2017 in a geographic area including Europe (France, Germany, Italy, Spain and the UK), Asia (Iran, Japan and China), North America (Canada and the US) and Australia was 20.6 billion USD. Cancer Intelligence 2018-11-26 /pmc/articles/PMC6345079/ /pubmed/30679950 http://dx.doi.org/10.3332/ecancer.2018.883 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Casamayor, Montserrat
Morlock, Robert
Maeda, Hiroshi
Ajani, Jaffer
Targeted literature review of the global burden of gastric cancer
title Targeted literature review of the global burden of gastric cancer
title_full Targeted literature review of the global burden of gastric cancer
title_fullStr Targeted literature review of the global burden of gastric cancer
title_full_unstemmed Targeted literature review of the global burden of gastric cancer
title_short Targeted literature review of the global burden of gastric cancer
title_sort targeted literature review of the global burden of gastric cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345079/
https://www.ncbi.nlm.nih.gov/pubmed/30679950
http://dx.doi.org/10.3332/ecancer.2018.883
work_keys_str_mv AT casamayormontserrat targetedliteraturereviewoftheglobalburdenofgastriccancer
AT morlockrobert targetedliteraturereviewoftheglobalburdenofgastriccancer
AT maedahiroshi targetedliteraturereviewoftheglobalburdenofgastriccancer
AT ajanijaffer targetedliteraturereviewoftheglobalburdenofgastriccancer